liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Human papillomavirus antibody responses among patients with incident cervical carcinoma.
The Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
The Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
Department of Gynecologic Oncology, Karolinska Institute, Stockholm, Sweden.
Department of Medical Microbiology, University of Mainz, Mainz, Germany.
Show others and affiliations
1997 (English)In: Journal of Medical Virology, ISSN 0146-6615, E-ISSN 1096-9071, Vol. 52, no 4Article in journal (Refereed) Published
Abstract [en]

The human papillomavirus (HPV) is recognized as a major cause of cervical cancer precursor lesions. HPV serology is a key method in the continuing elucidation of the importance of HPV exposure for cancer development and in predicting HPV-associated diseases. To extend previous HPV serological studies on cervical cancer, serum samples from a consecutive series of 216 women with incident untreated cervical carcinoma and 243 age- and sex-matched healthy blood donors were evaluated for the presence of antibodies against HPV capsids, a marker of past or present HPV exposure, as well as against several cervical cancer-associated defined HPV epitopes. Among the capsid antibody responses, HPV type 16 seropositivity had the strongest association with cervical cancer (OR 2.7, 95% CI 1.8-4.2), but HPV 18 and HPV 33 seropositivities were also significantly associated with cervical cancer (OR 1.6, 95% CI 1.1-2.5; and OR 1.5, 95% CI 1.0-2.2, respectively). The antibody responses against the defined HPV epitopes were confirmed to be associated with cervical cancer, at ORs ranging from 1.4 to 2.0. In conclusion, the study confirms that antibodies against defined HPV epitopes are associated with cervical cancer and provides evidence that seropositivities for HPV types 16, 18, and 33 are associated with cervical cancer risk.

Place, publisher, year, edition, pages
John Wiley & Sons, 1997. Vol. 52, no 4
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-133688DOI: 10.1002/(SICI)1096-9071(199708)52:4<436::AID-JMV16>3.0.CO;2-EPubMedID: 9260694OAI: oai:DiVA.org:liu-133688DiVA: diva2:1062619
Available from: 2017-01-07 Created: 2017-01-07 Last updated: 2017-01-22

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Åvall Lundkvist, Elisabeth
In the same journal
Journal of Medical Virology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf